帕博利珠单抗联合奥拉帕利对比帕博利珠单抗联合培美曲塞作为转移性非鳞状非小细胞肺癌维持治疗的3期KEYLYNK-006研究
KEYLYNK-006研究纳入经四周期帕博利珠单抗+培美曲塞+卡铂或顺铂诱导后获得完全缓解、部分缓解或疾病稳定的初治转移性非鳞状非小细胞肺癌患者,按1:1随机接受帕博利珠单抗联合奥拉帕利或帕博利珠单抗联合培美曲塞维持治疗。帕博利珠单抗联合奥拉帕利对比帕博利珠单抗联合培美曲塞未改善无进展生存期或总生存期。
要点
- 帕博利珠单抗联合奥拉帕利维持治疗的无进展生存期与总生存期均未优于帕博利珠单抗联合培美曲塞。
- 无进展生存期:奥拉帕利组7.1个月 vs 培美曲塞组8.3个月,HR=1.12,95%CI 0.92-1.36,p=0.87。
- 总生存期:奥拉帕利组20.7个月 vs 培美曲塞组23.0个月,HR=1.04,95%CI 0.87-1.25,p=0.6649。
核心结论
- 在既往未治疗、无靶向基因变异的转移性非鳞状非小细胞肺癌中,帕博利珠单抗联合奥拉帕利维持治疗对比帕博利珠单抗联合培美曲塞未改善无进展生存期或总生存期。
研究设计与样本
- 3期KEYLYNK-006试验(NCT03976323)。
- 符合条件的成人患者为既往未治疗、无靶向基因变异的转移性非鳞状非小细胞肺癌,且在接受四个周期的帕博利珠单抗200 mg每三周一次、培美曲塞500 mg/m2及卡铂浓度-时间曲线下面积5 mg/mL/min或顺铂75 mg/m2诱导治疗后达到完全缓解、部分缓解或疾病稳定。
- 患者按1:1随机接受奥拉帕利300 mg口服每日两次或培美曲塞每三周一次,两者均联合最多31个周期的帕博利珠单抗每三周一次。
- 双主要终点为无进展生存期和总生存期,无进展生存期在第2次中期分析(即最终无进展生存期分析)检验,总生存期在最终分析检验。
- 接受诱导治疗的1003例患者中,672例(67.0%)被随机分配至帕博利珠单抗联合奥拉帕利组(n=337)或帕博利珠单抗联合培美曲塞组(n=335),纳入意向治疗人群。
主要发现
- 最终分析时中位随访时间为39.9个月(范围28.1-51.5)。
- 第2次中期分析时,奥拉帕利组对比培美曲塞组的中位无进展生存期(95%CI)为7.1(5.6-8.7)个月 vs 8.3(6.9-11.5)个月,风险比=1.12,95%CI 0.92-1.36,p=0.87。
- 最终分析时,奥拉帕利组对比培美曲塞组的中位总生存期(95%CI)为20.7(18.0-24.8)个月 vs 23.0(19.0-26.4)个月,风险比=1.04,95%CI 0.87-1.25,p=0.6649。
- 3至5级维持治疗相关不良事件分别发生于奥拉帕利组26.1%与培美曲塞组30.1%的患者。
关键数值与推荐
- 无进展生存期:奥拉帕利组7.1个月(95%CI 5.6-8.7) vs 培美曲塞组8.3个月(95%CI 6.9-11.5),HR=1.12(95%CI 0.92-1.36),p=0.87。
- 总生存期:奥拉帕利组20.7个月(95%CI 18.0-24.8) vs 培美曲塞组23.0个月(95%CI 19.0-26.4),HR=1.04(95%CI 0.87-1.25),p=0.6649。
- 3至5级维持治疗相关不良事件:奥拉帕利组26.1% vs 培美曲塞组30.1%。
临床怎么用
- 帕博利珠单抗联合奥拉帕利维持治疗未改善无进展生存期或总生存期,原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Poly (adenosine diphosphate-ribose) inhibitors, including olaparib, upregulate programmed cell death ligand 1, which may increase the efficacy of anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapies. METHODS: In the phase 3 KEYLYNK-006 trial (NCT03976323), eligible adults with previously untreated metastatic nonsquamous NSCLC without targetable genetic alterations who had complete response, partial response, or stable disease after induction therapy with four cycles of pembrolizumab 200 mg every three weeks, pemetrexed 500 mg/m2, and carboplatin area under the concentration-time curve 5 mg/mL/min or cisplatin 75 mg/m2 were randomized in a one-to-one ratio to olaparib 300 mg orally twice daily or pemetrexed every three weeks, both given with up to 31 cycles of pembrolizumab every three weeks. Dual primary endpoints were progression-free survival (PFS) and overall survival (OS). Progression-free survival was tested at interim analysis 2 (i.e., final PFS analysis) and OS at final analysis (FA). RESULTS: Of 1003 patients who received induction therapy, 672 (67.0%) were randomized to pembrolizumab plus olaparib (n = 337) or pembrolizumab plus pemetrexed (n = 335) in the intention-to-treat population. Median follow-up at FA was 39.9 (range: 28.1-51.5) months. At interim analysis 2, the median (95% confidence interval [CI]) PFS was 7.1 (5.6-8.7) months versus 8.3 (6.9-11.5) months in the olaparib versus pemetrexed groups (hazard ratio = 1.12, 95% CI: 0.92-1.36, p = 0.87). At FA, the median (95% CI) OS was 20.7 (18.0-24.8) months versus 23.0 (19.0-26.4) months (hazard ratio = 1.04, 95% CI: 0.87-1.25, p = 0.6649). Grade 3 to 5 maintenance treatment-related adverse events occurred in 26.1% versus 30.1% of patients, respectively. CONCLUSION: Pembrolizumab plus maintenance olaparib did not improve PFS or OS versus pembrolizumab plus pemetrexed in previously untreated metastatic nonsquamous NSCLC without targetable genetic alterations.
引用
- Gray JE, Schenker M, Şendur MAN, et al. The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2024. PMID: 39521434. doi:10.1016/j.jtho.2024.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。